Pharmaceutical M&A, focus on selected therapeutic areas and in-licensing driven by rising drug development costs
First written in FY2023-Q2. 4 of 5 entries say "Restated". Latest entry: FY2025-H1.
1 other company's latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「In addition, rising new drug development costs due to factors such as larger clinical trials are driving consolidation among pharmaceutical companies in Japan and overseas, expanding company scale through M&A. Pharmaceutical companies are also narrowing their priority areas in internal drug discovery, while movements to bring in development programs from outside the company are becoming more active.」
新薬開発コスト増を背景に、製薬企業のM&A、重点領域の絞り込み、社外からの開発品目導入が進む業界構造を再掲している。 - FY2024-Q2RestatedAnnual report
「In addition, rising new drug development costs due to factors such as larger clinical trials are driving consolidation among pharmaceutical companies in Japan and overseas, expanding company scale through M&A. Pharmaceutical companies are also narrowing their priority areas in internal drug discovery, while movements to bring in development programs from outside the company are becoming more active.」
新薬開発コスト増を背景に、製薬企業のM&A、重点領域の絞り込み、社外からの開発品目導入が進む業界構造を再掲している。 - FY2024-Q1RestatedAnnual report
「In addition, rising new drug development costs due to factors such as larger clinical trials are driving consolidation among pharmaceutical companies in Japan and overseas, expanding company scale through M&A. Pharmaceutical companies are also narrowing their priority areas in internal drug discovery, while movements to bring in development programs from outside the company are becoming more active.」
新薬開発コスト増を背景に、製薬企業のM&A、重点領域の絞り込み、社外からの開発品目導入が進む業界構造を再掲している。 - FY2023-Q3RestatedAnnual report
「In addition, rising new drug development costs due to factors such as larger clinical trials are driving consolidation among pharmaceutical companies in Japan and overseas, expanding company scale through M&A. Pharmaceutical companies are also narrowing their priority areas in internal drug discovery, while movements to bring in development programs from outside the company are becoming more active.」
新薬開発コスト増を背景に、製薬企業のM&A、重点領域の絞り込み、社外からの開発品目導入が進む業界構造を再掲している。 - FY2023-Q2First statedAnnual report
「In addition, rising new drug development costs due to factors such as larger clinical trials are driving consolidation among pharmaceutical companies in Japan and overseas, expanding company scale through M&A. Pharmaceutical companies are also narrowing their priority areas in internal drug discovery, while movements to bring in development programs from outside the company are becoming more active.」
The company describes an industry structure in which rising development costs are driving pharmaceutical M&A, narrowing of priority areas and increased in-licensing of external development programs.